Final answer:
The 1983 Orphan Drug Act allows drugs to be produced for small patient populations even though it might not be profitable for drug companies.
Step-by-step explanation:
The statement is true. The 1983 Orphan Drug Act was enacted in the United States to incentivize the development of drugs for small patient populations, also known as orphan diseases. Orphan diseases are conditions that affect a small number of people, making it unprofitable for drug companies to invest in research and development for these drugs. The Orphan Drug Act provides incentives such as tax credits, grants, and exclusive marketing rights to encourage drug companies to develop treatments for these rare diseases.